Development of Continuous Glucose Monitoring System Cohort for Personalized Diabetes Prevention and Management Platform

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to collect a variety of clinical data and blood glucose changes using a continuous glucose monitoring device for high-risk diabetes patients (prediabetes) in order to develop a personalized diabetes prevention and management platform based on artificial intelligence model using mathematical analysis.

Detailed Description
-----------------
After being informed about the study and potential risks, all patients giving written informed consent wear a continuous glucose monitoring device (iPro2 professional continuous glucose monitoring, MedtronicⓇ, California, USA) and smart band (Fitbit Inspire HR, FitbitⓇ, California, USA) for 1 week. During this period, all patients are tested oral glucose tolerance test and take a standard diet (calorie calculated) at morning. The patient's data from this study is compared to a predicted values by mathematical analysis model for diabetes prevention.

Official Title
-----------------
Development of Continuous Glucose Monitoring System Cohort for Personalized Diabetes Prevention and Management Platform Based on Artificial Intelligence Model Using Mathematical Analysis

Conditions
-----------------
PreDiabetes, Glucose Metabolism Disorders, Diabetes Mellitus

Intervention / Treatment
-----------------
* Device: continuous glucose monitoring system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Above 18 years old. Prediabetes Fasting plasma glucose : 100 125mg/dL, fasting is defined as no caloric intake for at least 8 hours. OR 2-hour plasma glucose during 75g oral glucose tolerance test : 140   199mg/dL OR Glycated hemoglobin(HbA1c) : 5.7 6.4% (39-47mmol/mol) Exclusion Criteria: with a history of newly diagnosed and treated cancer within the last 5 years with a history of hospitalization for active disease within the last 3 months with a history of severe cardiovascular disease within the last 3 months with a history of steroid treatment in the last 3 months people who have had major surgery planned within the last 3 months or who have had surgery within 3 months people who are pregnant or have been in the last 3 months after giving birth

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| continuous glucose monitoring group<br>all participants wearing a continuous glucose monitoring device | Device: continuous glucose monitoring system<br>* wearing continuous glucose monitoring device (iPro2 professional continuous glucose monitoring, MedtronicⓇ, California, USA)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Insulin Resistance | the prevalence of insulin resistance in participants was measured. Insulin resistance was calculated by HOMA-IR(homeostatic model assessment of insulin resistance), QUICKI (quantitative insulin sensitivity check index) and Matsuda index | 1 week |